Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Federica R. Achini-Gutzwiller"'
Autor:
Federica R. Achini-Gutzwiller, Cornelia M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Arjan C. Lankester, Robbert G. M. Bredius, Maarten J. D. van Tol, Dirk Jan A. R. Moes, Marco W. Schilham
Publikováno v:
Therapeutic Drug Monitoring. 45:79-86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91b4550e643339ae76e1700351ec5a1d
https://doi.org/10.1097/ftd.0000000000001037
https://doi.org/10.1097/ftd.0000000000001037
Autor:
Federica R, Achini-Gutzwiller, Cornelia M, Jol-van der Zijde, Anja M, Jansen-Hoogendijk, Arjan C, Lankester, Robbert G M, Bredius, Maarten J D, van Tol, Dirk Jan A R, Moes, Marco W, Schilham
Publikováno v:
Therapeutic drug monitoring.
Alemtuzumab is a humanized monoclonal antibody that targets the CD52 glycoprotein expressed on most lymphocytes, subsequently inducing complement- and antibody-mediated cytotoxicity. Owing to its ability to induce profound immune depletion, alemtuzum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cb78139e7f32137c9e0e172e30ab144b
https://pubmed.ncbi.nlm.nih.gov/36150715
https://pubmed.ncbi.nlm.nih.gov/36150715